Development of new experimental models to understand the genetic basis of allergic bronchopulmonary aspergillosis (ABPA)
Development of new experimental models to understand the genetic basis of allergic bronchopulmonary aspergillosis (ABPA)
批准号:
NC/P002390/1
负责人:
Sara Gago
金额:
$15.08万
依托单位:
依托单位国家:
英国
项目类别:
Fellowship
财政年份:
2017
资助国家:
英国
项目状态:
已结题
起止时间:
2017 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Asthma is a major respiratory disease characterized by recurrent attacks of breathlessness and wheezing associated with allergen sensitization (e.g. pollen, house dust mite, fungi). In the UK, 5.4 million people have asthma with over 100,000 at risk on a progressive lung disease called allergic bronchopulmonary aspergillosis (ABPA). While the disease is not usually fatal, patients lives can be miserable and the economic impact is very high. ABPA affects people with a defective airway epithelial barrier function such as asthmatics but is further complicated by the growth of the fungal pathogen Aspergillus fumigatus in the airways. We are all exposed to A. fumigatus but <2% of that people gets ABPA, which might be due to a genetically determined deficiency in the patients lungs ability to fend off fungal establishment.To consider this possibility, the Manchester Fungal Infection Group (MFIG) has sequenced the genome of 242 people with ABPA looking for mutations that might explain the disease. We have found that five mutations are in genes probably involved in avoiding A. fumigatus to be cleared from the respiratory airways. However, the biological function of every single mutation needs to be defined. Classically, transgenic mouse carrying specific mutations have been used to define the biological function of genes. Nonetheless, asthma found in mice and that found in humans are not comparable; therefore a new model to study ABPA is needed. Thus, to study the pathology of ABPA, I propose the development of a human cell culture system comparing cells carrying the five mutations with normal cells. During the last 18 months, I have been working at MFIG developing an in-vitro model using bronchial epithelial cells carrying mutations associated with fungal diseases. Genome edition of cells has been done by using the CRISPR/Cas9 system that allows introducing mutations in cells without changing anything else in the genome. This model allows studying the effect of a single mutation by comparing genome-edited cells with normal ones. By using this model, I have described the role of a mutation in a transcription factor in ABPA patients which modulates A. fumigatus germination. However, there are other associated aspects like the allergic response in ABPA, which cannot be explained only by the transcription-factor mutation. I would now like to take this work forward with a NC3Rs fellowship by developing an in-vitro model to test the 5 mutated genes discovered in our genetics project described above. I will recreate the mutations in two different cell types, bronchial epithelial cells and macrophages, since they play an essential role in the ABPA immune response. I will challenge the mutated cells with Aspergillus spores and compare them to normal cells so the importance of both, cell type and genetic risk factor in the response against A. fumigatus will be explored. Besides, I will develop an in-vitro model to explore crosstalk interactions between epithelial cells and macrophages carrying the same mutation in order to determine if cell signalling is from epithelial cells to macrophages or the other way around during the initial steps of the immune response to A. fumigatus in ABPA. I will perform this ambitious objective by collaborating with researchers from the University do Minho, Portugal, who have a great deal of experience in studying the importance of genetic risk factors in the development of fungal diseases. Finally, my results will be confirmed by measuring the response against A. fumigatus in nasal brush and blood samples from ABPA patients with known genetic backgrounds and will then be compared with healthy donors. Samples will be obtained from the Manchester Respiratory and Allergy Biobank. This will allow a better approximation to the real situation in humans.Biotech companies might have a strong interest in this project as candidate genes for gene therapy or for drug development will be discovered from this job.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
脊髓新鉴定SNAPR神经元相关环路介导SCS电刺激抑制恶性瘙痒
-
批准号:82371478
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:焦英甫
-
依托单位:
tau轻子衰变与新物理模型唯象研究
-
批准号:11005033
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2010
-
负责人:李文君
-
依托单位:
HIV gp41的NHR区新靶点的确证及高效干预
-
批准号:81072676
-
项目类别:面上项目
-
资助金额:33.0万元
-
批准年份:2010
-
负责人:戴秋云
-
依托单位:
强子对撞机上新物理信号的多轻子末态研究
-
批准号:10675110
-
项目类别:面上项目
-
资助金额:36.0万元
-
批准年份:2006
-
负责人:蒋一
-
依托单位: